ClinicalTrials.gg
CompletedNCT00993109Updated Jun 5, 2014

Low-dose Nifedipine-Valsartan Combination Compared to Up-titrated Valsartan Monotherapy in Essential Hypertension

A Phase 4 interventional study of Adalat (Nifedipine, BAYA1040) and Diovan (Valsartan) in Hypertension, sponsored by Bayer. Completed at 17 sites in 2 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2014-06-05.

Sponsored by Bayer · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
360
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 29 studies testing nifedipine in Hypertension — 3 open to participants now, 3 under way, 1 of them phase 3. Nifedipine · Hypertension.

Enrollment
6th of 29
360 · median 72
Started
2010
with 2 others
Phase 4
12 of 29
1 open now
Registered
7th of 29
by date
Lead sponsor
11 of 29
Bayer

Among the 29 studies testing nifedipine in Hypertension, this one is the 6th largest by enrollment, is one of 3 that started in 2010, is one of 12 in phase 4, and was the 7th registered.

Hypertension

6,122 studies on the registry are indexed under Hypertension; 909 are open to participants now.

Browse Hypertension studies →

Open to participants now

3 of the 29 studies testing nifedipine in Hypertension are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About nifedipine

Nifedipine: first FDA approval 1981 (PROCARDIA). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 558 Hypertension studies recruiting now, 265 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies testing nifedipine in Hypertension, or all of them as a file.
02

Study summary

This will be a multi-center, prospective, randomized, open-label, parallel design, two arm comparator trial. In the proposed study, the investigators will compare low-dose combination therapy of Nifedipine GITS/OROS plus Valsartan with up-titrated monotherapy of Valsartan with respect to their blood pressure-decreasing effects in patients with essential hypertension.The study consists of a screening visit, followed by randomization and administration of either Nifedipine GITS/OROS 30 mg in combination with Valsartan 80 mg or Valsartan 160 mg for 12 weeks of treatment.The primary efficacy parameters will be mean SBP and DBP on office BP monitoring at 12 weeks of treatment compared to baseline.

03

Conditions studied

  • Hypertension

Browse trials for

Keywords

  • Nifedipine GITS/OROS (Adalat®)
  • Valsartan (Diovan®)
  • Hypertension
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men and women aged 18 - 75 years
  • Essential hypertension not well controlled by current low dose (80 mg) valsartan monotherapy for at least 4 weeks. Patients on prior treatment with monotherapy diuretic, ACE-I or beta blocker or an ARB other than valsartan and switched to the current low dose valsartan 80 mg monotherapy for at least 4 weeks are also eligible, provided the hypertension is still not well controlled.
  • Office systolic blood pressure (sitting) >140 mmHg (sitting for >/= 5 min., no cigarettes and/or coffee/tea for >/=30 min. before BP measurement).
  • \<33 kg/m2

Exclusion criteria

Exclusion Criteria:

  • Participation in any clinical drug study within the previous 12 weeks
  • Concomitant treatments with:

    1. Any anti-hypertensive treatment other than Valsartan 80 mg
    2. Cytochrome P450-3A4 inhibitors or inducers
    3. Potassium-sparing diuretics
  • Severe hypertension (DBP >/= 110 mm Hg and/or SBP >/= 180 mm Hg) and/or evidence of secondary forms of hypertension
  • Any of the following cardiovascular diseases:
  • History of cardiovascular shock
  • Myocardial infarction or unstable angina within the previous 6 months
  • Severe cardiac valve disease
  • Past or present severe rhythm or conduction disorder.
  • Cerebrovascular ischemic event and/or history of intracerebral hemorrhage or subarachnoid hemorrhage (SAH) within the previous 12 months
  • Type 1 or 2 diabetes mellitus
  • Proteinuria
  • Uncorrected hypokalemia or hyperkalemia, sodium depletion and/or hypovolemia
  • Gastrointestinal disease resulting in the potential for malabsorption and/or severe gastro-intestinal tract narrowing; kock pouch (ileostomy after proctocolectomy)
  • Cholestasis or biliary obstruction
  • Liver disease or (AST) / alanine aminotransferase (ALT) levels >3 x (ULN)
  • Renal failure, creatinine level >2.0 mg/dl
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
360 participants (actual)

Study arms

  • Experimental
    Arm 1

    Drug: Adalat (Nifedipine, BAYA1040)

  • Active comparator
    Arm 2

    Drug: Diovan (Valsartan)

Interventions

06

What researchers measure

Primary outcomes

  1. Mean Systolic BP and Diastolic BP on office Blood Pressure monitoring

    Time frame: Baseline and 12 weeks of treatment

Secondary outcomes

  1. Response rate (>/=10mmHg decrease of office SBP and >/=5mmHg decrease of office DBP)

    Time frame: 8 and 12 weeks of treatment

  2. Control rate (</=140/90 of office BP)

    Time frame: 8 and 12 weeks of treatment

  3. Change in pulse pressure (difference between SBP and DBP)

    Time frame: 12 weeks of treatment

  4. Reduction in Urinary microalbumin excretion(UAE) in patients with microalbuminuria

    Time frame: Baseline and 12 weeks of treatment

  5. Adverse Event reporting

    Time frame: At the start, every 4 weeks during treatment and at the end of treatment

  6. Vitals signs

    Time frame: At the start, every 4 weeks during treatment and at the end of treatment

  7. Laboratory tests

    Time frame: At the start and at the end of treatment

07

Study locations

17 sites
  • Guangzhou, Guangdong 510080, China
  • Shijiazhuang, Hebei 050051, China
  • Changsha, Hunan 410008, China
  • Changsha, Hunan 410013, China
  • Nanjing, Jiangsu 210008, China
  • Nanjing, Jiangsu 210029, China
  • Shenyang, Liaoning 110001, China
  • Beijing, 100029, China
  • Beijing, 100037, China
  • Shanghai, 200025, China
  • Donggu,, Gwangju Gwang''yeogsi 501757, Korea, Republic of
  • Bucheon-si,, Gyeonggido, Korea, Republic of
  • Yangsan-si, Gyeongnam, Korea, Republic of
  • Jongno-gu, Korea, Republic of
  • Jung-gu, Korea, Republic of
  • Seoul, 110-744, Korea, Republic of
  • Seoul, 120-752, Korea, Republic of
08

References and documents

Publications

  • Ke YN, Dong YG, Ma SP, Yuan H, Ihm SH, Baek SH; ADVISE study group. Improved blood pressure control with nifedipine GITS/valsartan combination versus high-dose valsartan monotherapy in mild-to-moderate hypertensive patients from Asia: results from the ADVISE study, a randomized trial. Cardiovasc Ther. 2012 Dec;30(6):326-32. doi: 10.1111/1755-5922.12003. PubMed 23134522 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2010, a primary completion of May 2011 and a completion of May 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 9, 2009
First posted
Oct 12, 2009
Start
Feb 2010
Primary completionActual
May 2011
CompletionActual
May 2011
Last update
Jun 5, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 5, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00993109
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Oct 12, 2009
Start date
Feb 2010
Primary completion
May 2011
Completion
May 2011
Last update
Jun 5, 2014

Study contacts

Bayer Study Director
study director · Bayer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nifedipine

Start the discussion